| g. more about bipolar mania. The concomitant of Cymbalta with serotonin precursors (such as ) is not recommended (see PRECAUTIONS , DRUG INTERACTIONS ). The no-effect dose was 50 mg/kg/day (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m 2 basis). In controlled trials in , elevations of ALT to >3 times the upper limit of normal occurred in 1. The concomitant use of Cymbalta with MAOIs intended to treat depression is contraindicated (see CONTRAINDICATIONS and WARNINGS , Potential for Interaction with Monoamine Oxidase Inhibitors). WebMD Drug News Avandia To Despite Heart Attack Risk Osteoporosis Drug May Fight Osteoarthritis Suspended IBS Drug Zelnorm OK'd For Some Read More » Take Control of Your Depression! Some cases were possibly due to the of inappropriate antidiuretic hormone secretion (SIADH). Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see DOSAGE AND ADMINISTRATION ). The following symptoms, anxiety , agitation, panic attacks, insomnia , irritability, hostility, aggressiveness, impulsivity , akathisia (psychomotor restlessness), hypomania , and mania , have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, psychiatric and nonpsychiatric? 8 mm Hg (systolic) and 4. All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a of drug therapy, or at of dose changes, either increases or decreases. g. However, fetal weights were decreased at this dose, with a no-effect dose of 10 mg/kg/day (2 times the MRHD and 1 times the human dose of 120 mg/day on a mg/m 2 basis in rat; 3 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m 2 basis in rabbits). Therefore, because Cymbalta is an inhibitor of both serotonin and norepinephrine reuptake, it is recommended that Cymbalta not be used in combination with an MAOI, or at least 14 days of discontinuing treatment with an MAOI. Following abrupt discontinuation in placebo-controlled clinical trials of up to 10-weeks duration, the following symptoms occurred at a rate greater than or equal to 2% and at a significantly higher rate in either the MDD or GAD Cymbalta-treated patients to those discontinuing from placebo: dizziness ; nausea; headache ; paresthesia ; vomiting; irritability; and nightmare. In placebo-controlled clinical trials, seizures/convulsions occurred in 0. Orthostatic Hypotension and Syncope Orthostatic hypotension and syncope have been reported with therapeutic doses of duloxetine. In the 12-week acute treatment phase of these studies, was associated with a small increase in mean fasting blood glucose as compared to placebo. Patients should be given the opportunity to discuss the contents of Medication Guide and to obtain answers to any questions they may have. |